Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of ZN-d5 in Healthy Female Volunteers
NCT04854174Phase 1Completed
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of asaretoclax in hematologic malignancy, sponsored by Zentalis Pharmaceuticals. Primary endpoint: ZN-d5 Bioavailability at 2 months. Started Jun 2021; status: completed.
02
Drugs
asaretoclax
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT04854174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854174.